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Background: The underlying mechanism of the association between thyroid function and 
atrial fibrillation (AF) is poorly understood, but epicardial adipose tissue (EAT) could be a 
promising mediator.
Methods: In the 1995 participants (mean age 64.5 years) from the population-based Rotterdam 
Study, we measured thyroid function (thyroid-stimulating hormone, free thyroxine [FT4]) and 
performed computed tomography to quantify EAT volumes. All participants were followed for 
the occurrence of AF. We assessed associations of thyroid-stimulating hormone and FT4 with 
EAT and AF and performed causal mediation analysis to decompose the overall effect of thyroid 
function on AF with EAT as mediator.
Results: Higher FT4 levels were associated with larger EAT volumes in persons with large waist 
circumferences, defined by sex-specific cutoffs (0.08 mL more EAT per 1-SD increase in FT4, 
95% CI: 0.02, 0.14), but not in persons with a normal waist circumference. In persons with a 
large waist circumference, higher FT4 levels were associated with a higher AF risk (hazard ratio 
1.50, 95% CI: 1.22, 1.83). We found no evidence of a mediating role of EAT in the association 
of thyroid function with AF (mediated interaction 1.6%, pure indirect effect 3.2%). The estimate 
of reference interaction of EAT with thyroid function on AF risk was more substantial (10.8%), 
but statistically nonsignificant.
Conclusions: Higher FT4 levels are associated with larger EAT volumes in persons with 
abdominal obesity. We report no mediating role of EAT in the association of thyroid function 
with AF, but found evidence for a suggested interaction of FT4 with EAT volumes on AF risk.
Keywords: thyroid function, epicardial fat, atrial fibrillation, causal mediation analysis
Introduction
The association of high and high-normal thyroid function with atrial fibrillation (AF) 
has been established in several large studies and meta-analyses.1–3 Possible pathophysi-
ological mechanisms include direct effects of thyroid hormone on the sympathetic 
nervous system and indirect effects through accumulation of cardiovascular risk factors. 
However, the link between thyroid function and AF seems largely independent of tra-
ditional cardiovascular risk factors such as blood pressure, diabetes, and cholesterol.1,2 
This suggests that yet unexplored cardiovascular risk factors or alternative pathways 
could mediate the association of thyroid dysfunction with AF. Further elucidation of 
these mediators is not only important for pathophysiological understanding but, pos-
sibly, also for future treatment decisions (i.e., treatment targeted at thyroid dysfunction, 
modifiable mediators, or both).
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Against this background, epicardial adipose tissue (EAT) 
might be of great interest. EAT is a rapidly emerging risk 
factor for cardiovascular disease, and particularly for AF.4,5 
Thyroid hormones may be linked to EAT through several 
mechanisms. For example, thyroid hormones act on pathways 
leading to atherogenesis, including endothelial damage and 
increased procoagulation factors,6 which are in turn closely 
related to EAT increase. Thyroid hormones may also exert 
direct effects on EAT by activating adipose tissue, mainly 
brown adipose tissue. Thyroid hormones are important for 
energy regulation and thermogenesis. Thyroid hormone 
excess leads to an increase in basal metabolic rate and ther-
mogenesis, and patients with hyperthyroidism often present 
with weight loss. However, thyroid hormones have also been 
shown to play a role in brown adipose tissue activity and white 
adipose tissue browning.7 In mice, lack of thyroid hormone 
reduces activity of brown adipose tissue, while hyperthyroid-
ism shows an increase in brown adipose tissue mass.8 EAT 
is generally perceived as solely consisting of white adipose 
tissue.4 This concept is under debate since brown adipose 
tissue-specific genes, UCP1 gene in particular, have been 
identified in human EAT, suggesting that EAT additionally 
possesses brown adipose tissue-like characteristics.4
Hence, EAT may represent a potential explanation for the 
association of high thyroid function with AF. In the past years, 
several small studies (n<100 participants) have indicated a 
possible role of hypothyroidism or hyperthyroidism on EAT 
formation and progression.9–13 This association has neither 
been explored in larger studies, nor has it been investigated 
in the full range of thyroid function in the general population. 
Hence, we aimed to assess the association of thyroid function 
with EAT measured by computed tomography and to investi-
gate whether EAT is a mediator of the association of thyroid 
function with AF in a large population-based cohort study.
Methods and materials
Setting and study population
The study was performed in the context of the Rotterdam 
Study (RS), a prospective population-based cohort study that 
investigates determinants and occurrence of cardiovascular, 
neurological, ophthalmologic, psychiatric, and endocrine dis-
eases in the middle-aged and elderly population. The aims and 
design of the Rotterdam Study have been described in detail 
elsewhere.14 We included participants from two independent 
cohorts within the Rotterdam Study. The first subcohort (RSI) 
includes participants aged ≥55 years, and baseline data were 
collected during 1990–1993. The second subcohort (RSII) 
includes participants aged ≥55 years, and baseline data were 
collected from 2000 to 2001. Between 2003 and 2006, all 
participants who visited the research center were invited to 
undergo a multidetector computed tomography (MDCT) 
examination on which the amount of epicardial fat was 
assessed. This was part of a larger project on the assessment of 
vascular calcification. In total, 2524 participants were scanned.
The study protocol was approved by the Medical Ethics 
Committee of the Erasmus University and by the Ministry of 
Health, Welfare and Sport of the Netherlands, implementing 
the “Wet Bevolkingsonderzoek: ERGO (Population Studies 
Act: Rotterdam Study)”. All included participants provided 
written informed consent in accordance with the Declaration 
of Helsinki to participate in the study and to obtain informa-
tion from their family physicians.
For the current study, we included all participants from 
the Rotterdam Study, cohort I wave 3 and cohort II wave 1, 
with available thyroid function measurements, CT EAT 
measurements (assessed after laboratory measurement in 
all participants), and data on AF incidence. We excluded 
participants using thyroid function altering medication (levo-
thyroxine, antithyroid drugs, amiodarone, or corticosteroids) 
and with prevalent AF at baseline. Eligible participants were 
followed up for incident AF events from CT EAT measure-
ment onward. Detailed information on the selection of study 
participants is provided in Figure 1.
Assessment of thyroid function
Thyroid function was measured through thyroid-stimulating 
hormone (TSH) and free thyroxine (FT4) using the same 
methods and assay for all cohorts (The electrochemilumines-
cence immunoassay for thyroxine and thyrotropin [ECLIA], 
Roche Diagnostics International Ltd, Rotkreuz ZG, Switzer-
land) in serum samples stored at −80°C. We determined the 
reference values for normal range TSH as 0.4–4.0 mIU/L and 
for FT4 as 11–25 pmol/L (=0.85–1.95 ng/dL) according to 
national guidelines as well as our previous studies.1,15
Assessment of epicardial fat volume
Non-contrast MDCT images were acquired using 16-slice 
(n=593) or 64-slice (n=1402) MDCT scanners (Somatom Sen-
sation 16 or 64, Siemens, Forchheim, Germany). Detailed infor-
mation on the imaging parameters are described  elsewhere.16 
We used an ECG-gated cardiac scan to visualize the epicardium, 
and applied a previously described, fully automatic tool to 
quantify the amount of epicardial fat in milliliters.17
Assessment of atrial fibrillation
For the assessment of AF during follow-up, three methods 
are used in the Rotterdam Study and have been described 
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in detail previously.18,19 First, electrocardiograms (ECGs) 
were recorded at study entry and at each follow-up examina-
tion and analyzed with the Modular ECG Analysis System 
(MEANS).20,21 All ECGs with a diagnosis of AF, atrial flutter, 
or any other rhythm disorder were reviewed by two indepen-
dent research physicians who were blinded to the MEANS 
diagnosis. In case of disagreement, a senior specialist was 
consulted and the final decision was made. Second, infor-
mation on AF was obtained through general practitioners’ 
records, which included their own results as well as hospital 
discharge letters and outpatient clinic reports. Third, the 
national medical registry of all hospital discharge diagno-
ses was linked to the Rotterdam Study database. Any cases 
detected through linkage were verified by review of the medi-
cal records. Participants who developed AF as a consequence 
of severe systemic illness (e.g., septic shock), resulting in 
death shortly after the detection of AF, were not considered to 
have AF. Furthermore, participants with transitory AF during 
myocardial infarction (MI) or after thoracic surgery were not 
considered as AF cases. All potential new diagnoses of AF 
were adjudicated by two independent research physicians, 
and in case of disagreement, consensus was sought. In case 
of persistent disagreement, a senior specialist made the final 
decision. Given that AF and atrial flutter are similar with 
respect to risk factors and consequences, these conditions 
were combined into a single composite outcome.22 Follow-up 
for AF was completed by January 1, 2014.
Assessment of other variables
We collected detailed information on cardiovascular risk 
factors and medication use in a standardized fashion by 
interview, physical examination, and blood sampling. Waist 
circumference was measured and expressed in centimeters. 
Waist circumference was stratified according to sex-specific 
clinical cutoffs. For women, normal waist circumference 
was defined as ≤88 cm, while large waist circumference 
was defined as >88 cm. For men, normal waist circumfer-
ence was defined as ≤102 cm, while large waist circumfer-
ence was defined as >102 cm. Systolic and diastolic blood 
pressure were measured twice at the right brachial artery 
using random-zero sphygmomanometer, and the mean of 
the two measurements was used for analyses. Fasting blood 
samples were obtained, and serum total cholesterol and 
high-density lipoprotein (HDL) cholesterol were measured 
using an automatic enzymatic procedure (Hitachi analyzer, 
Roche Diagnostics). Information on lipid-lowering and 
antihypertensive medication use was derived from question-
naires and pharmacy information. Smoking information 
was derived from baseline questionnaires and categorized 
into never, previous, and current smokers. Alcohol use 
information was derived from questionnaires and recorded 
as grams per day. History of diabetes was defined by a 
repeated (two measurements within 1 year) impaired fast-
ing glucose ≥7 mmol/L or a non-fasting glucose ≥7 mmol/L 
(when fasting samples were absent) or use of anti-glycemic 
Figure 1 Flowchart for the selection of study participants.
Notes: Baseline measurements for the present study were performed during the cohort I wave 3 and cohort II wave 1 of the Rotterdam Study. Thyroid function was 
assessed at baseline. Epicardial adipose tissue volumes were measured by CT scans, which were performed in cohort I wave 4 and cohort II wave 2 of the Rotterdam Study. 
The median time between CT scans and laboratory measurements was 4.6 years. Eligible participants were followed up for incident AF events from CT assessment onward.
Abbreviations: AF, atrial fibrillation; CT, computed tomography.
2265 with CT scan
139 had invalid CT scan (e.g.
artifacts)
7 participants had no thyroid
function measurements
83 had thyroid function altering
medication
41 had no information on incident
or prevalent AF
1995 included
participants
2036 had CT and thyroid
function and no medication
2126 had valid CT scan
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medication at baseline.  Prevalent  coronary heart disease was 
ascertained as previously described and consisted of a prior 
MI or revascularization.19
Statistical analyses
We analyzed the association of thyroid function (i.e., FT4 
or TSH) with EAT with ordinary least-squared regression 
models. The association of thyroid function or EAT with 
AF was investigated by Cox-proportional hazards regres-
sion models. We used restricted cubic splines at three knots 
for all covariates in our analyses to assess and account for 
possible nonlinearity of the associations, but no evidence of 
nonlinearity was observed.
All primary analyses were performed for three models. 
Potential confounders were selected based on biological 
plausibility and previous literature (Figures S1–S5). The 
first model was adjusted for age, sex, cohort, smoking, 
alcohol use, and time between laboratory measurement and 
CT scan. In the second model, we additionally adjusted for 
cardiovascular risk factors, including total cholesterol, HDL 
cholesterol, lipid-lowering medication, systolic blood pres-
sure, diastolic blood pressure, antihypertensive medication 
prevalent diabetes, and prevalent coronary heart disease. The 
third model was additionally adjusted for waist circumference 
(within the waist circumference categories). Of note, the first 
model was regarded as the primary model for the analyses 
where thyroid function is the exposure, because all included 
covariates in the other models are more likely to be possible 
mediators rather than confounders. For the analyses where 
EAT is the exposure and AF is the outcome, we additionally 
adjusted for TSH and FT4 and considered model 2 as the 
primary model (Figures S1–S4).
Due to the possible differential effect of thyroid function 
on adiposity in general, in contrast to EAT specifically, we 
tested interaction of TSH and FT4 with waist circumference 
on the association with EAT and AF. There was a statistically 
significant interaction between FT4 and waist circumference 
on EAT and on the risk of AF, and we therefore stratified the 
analyses according to sex-specific clinical cutoffs of waist cir-
cumference. We considered waist circumference rather than 
BMI as a marker of obesity, because 1) waist circumference is 
perceived as a better marker of visceral adiposity as compared 
to BMI and 2) waist circumference showed better statistical 
properties as compared to BMI (e.g., statistical significance 
for the interaction terms while avoiding multicollinearity 
that occurred when introducing both waist circumference 
and BMI to the model). The association of thyroid function 
with waist circumference in our study is provided in Table S1. 
There was no interaction of thyroid function with sex or age 
on any of the outcomes.
Given a possible synergic effect of thyroid function and 
EAT volumes on AF risk, our mediation analysis was based on 
the approach of a four-way decomposition, which combines 
methods assessing mediation and interaction. In the four-way 
decomposition approach, the overall effect of thyroid func-
tion on AF with EAT as mediator (with which the thyroid 
function may interact) is decomposed into four components: 
1) the direct effect of thyroid function (i.e., TSH or FT4) on 
AF in the absence of EAT, 2) the interactive effect when the 
EAT is at the value it would be in the absence of the thyroid 
function, 3) a mediated interaction (due to mediation and 
interaction by EAT), and 4) a pure mediated effect.23 These 
concepts will be referred to as controlled direct effect, refer-
ence interaction, mediated interaction, and pure indirect effect, 
respectively. The method assumes baseline covariates control 
for exposure-outcome, mediator-outcome, and exposure-
mediator confounding and that there is no mediator-outcome 
relationship affected by exposure. In order not to violate the 
final condition, we used the predicted value of these factors on 
EAT: total cholesterol, HDL cholesterol, lipid-lowering medi-
cation, diastolic blood pressure, systolic blood pressure, blood 
pressure-lowering medication, prevalent CHD, and prevalent 
diabetes as covariates. We performed a sensitivity analysis 
including these variables separately in the mediation analysis 
(Table S2), but no meaningful differences were detected.
We used Z-scores of FT4, TSH, and EAT for all analyses, 
after log-transformation, when appropriate. Statistical analy-
ses were conducted using R statistical software (rms, Himsc, 
visreg packages, R-project, Institute for Statistics and Math-
ematics, R Core Team [2013], Vienna, Austria, version 3.0.2).
Results
We included 1995 participants with valid CT scans, thyroid 
function measurements, and information on AF follow-
up that did not use thyroid-function altering medication 
( Figure 1). Baseline characteristics of study participants, total 
and stratified by waist circumference, are shown in Table 1.
During an overall median follow-up of 12.9 years (inter-
quartile range [IQR] 12.07, 13.70), 109 of 1189 participants 
with a normal waist circumference and 87 of 806 participants 
with a large waist circumference developed AF.
Thyroid function and EAT
There was no association of TSH or FT4 with EAT in par-
ticipants with a normal waist circumference (Table 2). In 
participants with a large waist circumference, higher values 
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of FT4, but not TSH, were associated with a larger volume 
of EAT (Beta 0.08 per standardized FT4, 95% CI: 0.02, 0.14; 
Table 2). This is in contrast to the association of FT4 with 
waist circumference, where higher FT4 levels were associ-
ated with a lower risk of having a large waist circumference 
(odds ratio 0.84, 95% CI: 0.74, 0.94 per one Z-score increase 
of FT4; Table S1)
Thyroid function, EAT, and AF
In participants with a normal waist circumference, TSH 
and FT4 were not associated with incident AF, while larger 
 volumes of EAT were associated with an increased risk of 
AF with an hazard ratio (HR) of 1.53 per standardized EAT 
(95% CI: 1.19, 1.97; Table 3). In participants with large 
waist circumference, TSH was not associated with AF risk. 
However, FT4 and EAT were both associated with AF risk 
with HRs of 1.45 (95% CI: 1.20, 1.76) and 1.38 (95% CI: 
1.00, 1.89), respectively (Table 3).
None of the estimated excess risks of the four components 
was statistically significant (Table 4). The largest proportion 
attributable to the effect of FT4 on AF in participants with 
a large waist circumference was the controlled direct effect 
Table 1 Baseline characteristics of study participantsa
Characteristic Total sample, n=1995 Small waist 
circumference, n=1189
Large waist  
circumference, n=806
Age, years 64.5 (6.4) 64.4 (6.3) 64.7 (6.5)
Age, range 55–94 55–90 55–94
Women sex, n (%) 1018 (51.0) 516 (43.4) 502 (62.3)
TSH, mIU/mL, median (IQR) 1.84 (1.27–2.72) 1.78 (1.22–2.61) 1.92 (1.33–2.90)
FT4, pmol/L 15.6 (2.1) 15.8 (2.1) 15.4 (2.2)
Waist circumference, cm 93.4 (11.0) 87.7 (8.4) 101.7 (8.8)
BMI, kg/m2 27.0 (3.8) 25.0 (2.5) 29.9 (3.5)
Diabetes, n (%) 194 (9.7) 64 (5.4) 130 (16.1)
Total cholesterol, mmol/L 5.82 (0.96) 5.79 (0.94) 5.86 (0.98)
Serum lipid-lowering medication 256 (12.8) 120 (10.1) 136 (16.9)
HDL cholesterol, mmol/L 1.39 (0.37) 1.44 (0.39) 1.31 (0.34)
Systolic BP, mmHg 141.5 (20.6) 139.5 (20.7) 144.5 (20.2)
Diastolic BP, mmHg 78.4 (10.8) 77.6 (10.8) 79.6 (10.8)
Blood pressure-lowering medication, n (%) 511 (25.6) 229 (19.3) 282 (35.0)
Smoking
Current, n (%) 348 (17.3) 217 (18.3) 131 (16.3)
Past, n (%) 1039 (52.1) 605 (50.9) 434 (53.8)
Never, n (%) 608 (30.6) 366 (30.8) 240 (29.9)
Alcohol use, median (IQR) 10.0 (1.4–20.0) 10.0 (1.9–20.0) 9.7 (1.0–20.0)
Prevalent CHD, n (%) 104 (5.2) 61 (5.1) 43 (5.3)
Epicardial fat volume, median (IQR) 101.4 (80.0–130.4) 92.9 (72.9–118.4) 115.4 (93.7–148.2)
Time between laboratory measurement and scan, 
years, median (IQR)
4.6 (4.4–4.8) 4.6 (4.4–4.8) 4.6 (4.3–4.6)
Note: aValues are means and (SD) unless otherwise specified.
Abbreviations: BMI, body mass index; BP, blood pressure; CHD, coronary heart disease; FT4, free thyroxine; HDL, high-density lipoprotein; IQR, inter-quartile range; 
TSH, thyroid-stimulating hormone.
Table 2 Association of TSH or FT4 with EAT stratified for waist circumferencea
Variable Model 1, Beta (95% CI) Model 2, Beta (95% CI) Model 3, Beta (95% CI)
Small WC, N=1189
TSH 0.03 (−0.01, 0.07) 0.01 (−0.03, 0.06) 0.03 (−0.01, 0.07)
FT4 0.02 (−0.04, 0.08) 0.03 (−0.02, 0.09) 0.03 (−0.01, 0.03)
Large WC, N=806
TSH 0.01 (−0.05, 0.06) −0.00 (−0.05, 0.05) −0.00 (−0.05, 0.05)
FT4 0.08 (0.02, 0.14) 0.09 (0.02, 0.15) 0.10 (0.04, 0.16)
Notes: Model 1 = age, sex, cohort, alcohol, smoking, and time between laboratory measurement and scan; Model 2 = Model 1 + total cholesterol, HDL cholesterol, serum 
lipid-lowering medication, systolic blood pressure, diastolic blood pressure, blood pressure-lowering medication, prevalent diabetes, prevalent CHD; Model 3 = Model 2 + 
WC at baseline. aFor both thyroid function parameters and EAT, Z-scores were used in the analysis. WC was stratified according to sex-specific clinical cutoffs. For women, 
small WC was defined as ≤88 cm, while large WC was defined as >88 cm. For men, small WC was defined as ≤102 cm, while large WC was defined as >102 cm.
Abbreviations: CHD, coronary heart disease; EAT, epicardial fat tissue; FT4, free thyroxine; HDL, high-density lipoprotein; TSH, thyroid-stimulating hormone; WC, waist 
circumference.
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(84.4%; excess risk 0.424, 95% CI: −0.065, 0.711; Table 4). 
The remainder of the overall effect was due to reference 
interaction (i.e., the interactive effect between FT4 and EAT 
when the EAT is at the value it would be in the absence of 
the thyroid function) with a proportion attributable of 10.8% 
(excess risk 0.054, 95% CI: −0.138, 0.242). The natural 
indirect effect (i.e., sum of pure indirect effect and mediated 
interaction) was 0.024 (95% CI: −0.043, 0.063; Table 4).
Discussion
In this large sample of community-dwelling middle-aged and 
elderly subjects, higher FT4 levels among participants with 
a large waist circumference were associated with larger EAT 
volumes. Among participants with a normal waist circumfer-
ence, we observed no association between thyroid function 
and EAT volumes. The known relationship between higher 
thyroid function and AF was not mediated by EAT.
Similar to previous studies, we found high and high- 
normal thyroid hormone levels to be associated with an 
increased risk of AF.1,24 Prior prospective research has also 
reported a positive association of EAT volumes with AF 
risk.25 Interestingly, a thyroid hormone-dependent gene, 
namely uncoupling protein-1 (UCP1) gene, is highly 
expressed in EAT,26,27 thus suggesting a potential direct effect 
of thyroid hormones on mitochondrial uncoupling and in 
turn on EAT activation. In our study, we indeed describe an 
association of higher FT4 levels with larger EAT volumes, 
mainly among participants with a large waist circumfer-
ence. Therefore, we can speculate that higher FT4 levels 
among participants with abdominal obesity may addition-
ally increase the likelihood of having larger EAT volumes 
and the risk of developing AF. Due to the negative feedback 
mechanism of hypothalamic–pituitary–thyroid axis, one 
would expect TSH levels to be inversely associated with 
EAT. However, TSH levels were not associated with EAT 
volumes in our study. We hypothesize that this may reflect 
a dysregulation of the hypothalamic– pituitary–thyroid axis 
by overproduction of leptin in the setting of abdominal 
obesity.28,29
The relation of thyroid function with obesity is  complex.30 
As described in previous literature and confirmed in our 
study, FT4 levels are known to be negatively associated 
with abdominal obesity, which is in turn linked to increased 
EAT volumes.30 However, in our study, there was a positive 
association of FT4 levels with EAT volumes, which remained 
consistent after additionally adjusting for waist circumfer-
ence. These results indicate that waist circumference does 
Table 3 Association of TSH, FT4, and EAT with atrial fibrillation, stratified by waist circumference
Variable Events/Total, n Model 1, HR (95% CI) Model 2, HR (95% CI) Model 3, HR (95% CI)
Small WC 109/1189
TSH 1.10 (0.89, 1.35) 1.10 (0.90, 1.35) 1.12 (0.91, 1.38)
FT4 1.09 (0.90, 1.33) 1.09 (0.90, 1.33) 1.10 (0.90, 1.34)
EAT 1.50 (1.18, 1.91) 1.53 (1.19, 1.97) 1.48 (1.12, 1.96)
Large WC 87/806
TSH 0.90 (0.74, 1.09) 0.90 (0.74, 1.10) 0.88 (0.72, 1.07)
FT4 1.45 (1.20, 1.76) 1.46 (1.19, 1.78) 1.50 (1.22, 1.83)
EAT 1.37 (1.01, 1.86) 1.38 (1.00, 1.89) 1.22 (0.87, 1.70)
Notes: Model 1 = age, sex, cohort, alcohol, smoking, and time between laboratory measurement and scan. Model 2 = Model 1 + total cholesterol, HDL cholesterol, serum 
lipid-lowering medication, systolic blood pressure, diastolic blood pressure, blood pressure-lowering medication, prevalent diabetes, prevalent CHD. Model 3 = Model 2 + 
WC at baseline. For all EAT analyses models additionally adjusted for TSH and FT4. WC was stratified according to sex-specific clinical cutoffs. For women, small WC was 
defined as ≤88 cm, while large WC was defined as >88 cm. For men, small WC was defined as ≤102 cm, while large WC was defined as >102 cm.
Abbreviations: CHD, coronary heart disease; EAT, epicardial fat tissue; FT4, free thyroxine; HDL, high-density lipoprotein; TSH, thyroid-stimulating hormone; WC waist 
circumference.
Table 4 Proportions of the effect of FT4 on AF due to mediation 
and/or interaction with EAT
Characteristic Excess 
risk
95% CI Proportion  
attributable, %
Small WC
CDE 0.077 (−0.150, 0.285) 897
INTref −0.001 (−0.062, 0.018) −10
INTmed 0.002 (−0.009, 0.009) 2.5
PIE 0.008 (−0.016, 0.025) 8.8
Total 0.085 (−0.151, 0.276) 100
Large WC
CDE 0.424 (−0.065, 0.711) 84.4
INTref 0.054 (−0.138, 0.242) 10.8
INTmed 0.008 (−0.030, 0.038) 1.6
PIE 0.016 (−0.024, 0.036) 3.2
Total 0.502 (0.085, 0.733) 100
Notes: WC was stratified according to sex-specific clinical cutoffs. For women, 
small WC was defined as ≤88 cm, while large WC was defined as >88 cm. For 
men, small WC was defined as ≤102 cm, while large WC was defined as >102 cm. 
Analyses for the association of FT4 with EAT and AF were adjusted for age, sex, 
cohort, alcohol, and smoking. Analyses for the association of EAT with AF were 
additionally adjusted for total cholesterol, HDL cholesterol, serum lipid-lowering 
medication, systolic blood pressure, diastolic blood pressure, blood pressure-
lowering medication, prevalent diabetes, prevalent CHD, TSH, and FT4 levels.
Abbreviations: AF, atrial fibrillation; CDE, controlled direct effect; CHD, 
coronary heart disease; EAT, epicardial fat tissue; FT4, free thyroxine; HDL, high-
density lipoprotein; INTref, reference interaction; INTmed, mediated interaction; PIE, 
pure indirect effect; TSH, thyroid-stimulating hormone; WC, waist circumference.
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not explain the link between thyroid hormone and EAT. The 
opposing association of FT4 levels with EAT volumes as 
compared to FT4 levels with waist circumference could sug-
gest that the role of thyroid hormones on body fat distribution 
depends on the location and composition of visceral adipose 
tissue (e.g., presence of brown adipose tissue-like character-
istics or lack thereof). Along with other stimuli, increased 
thyroid hormones can enhance the transdifferentiation of 
white adipocytes to brown adipocytes in the EAT of obese 
patients. However, further research is needed to elucidate 
the exact mechanisms underlying the association of thyroid 
function with abdominal obesity and EAT.
Our study suggests that abdominal obesity may potenti-
ate the effect of FT4 on the development of AF. Among our 
participants with abdominal obesity, we found no evidence 
that the association between FT4 and AF was mediated by 
EAT. Alternative mechanisms other than EAT could, there-
fore, explain the link between thyroid function and AF. For 
example, thyroid hormones may contribute to the initiation 
and maintenance of AF via the activation of automatic foci 
in the pulmonary veins,31,32 the stimulation of sympathetic 
nervous system,33,34 the elevation of left atrial pressure 
secondary to ventricular hypertrophy, and atrial ischemia 
secondary to an increased heart rate,35 among others. On the 
other hand, we observed a notable proportion of reference 
interaction (10.8%), which indicates that the occurrence of 
AF can be partly explained by synergistic effects between 
thyroid hormones and EAT, though the 95% CI was quite 
wide. The results of our mediation analyses, however, should 
be interpreted with caution, as we may have lacked a suf-
ficient sample size to detect statistically significant findings.
To our knowledge, this is the largest population-based 
cohort study investigating the relationship of thyroid func-
tion with EAT volumes. Moreover, this is the first study that 
explores the potential mediating role of EAT in the associa-
tion between thyroid function and AF. The mediation analysis 
was based on the approach of a four-way decomposition, 
which unifies within a single framework the methods assess-
ing mediation and interaction.23 The detailed information on 
potential confounders allowed us to perform multivariate-
adjusted analyses. Another strength of our study is the 
comprehensive adjudication of end points. AF cases were 
extensively evaluated at baseline and during follow-up. EAT 
was assessed by using a standardized computed tomography- 
based procedure. Though most previous studies have utilized 
ultrasound measurements to evaluate EAT, computed tomog-
raphy is considered superior to the ultrasound in the detection 
and, particularly, in the quantification of EAT.13,36
Several limitations of our study should also be considered. 
Thyroid function and EAT volumes were assessed only once 
and we had no information regarding their changes over time. 
However, due to the intra-individual variability of TSH and 
FT4 levels, the lack of repeated measurements would tend 
to underestimate rather than overestimate the association 
of thyroid function with EAT and AF.37 EAT volumes were 
assessed after the thyroid function measurements (median 
time between CT scans and laboratory measurements was 
4.6 years). However, we adjusted all analyses for the time 
interval between the measurements. Another limitation is the 
lack of information on serum triiodothyronine levels. How-
ever, TSH and FT4 represent the most relevant measurements 
of thyroid function in clinical practice. The majority of our 
participants were white middle-aged and older adults, limit-
ing the generalizability of our findings to other populations. 
Lastly, given the observational study design, we cannot rule 
out the possibility of residual or unmeasured confounding.
Our findings suggest that in subjects with abdominal 
obesity, FT4 measurement can help identify those with larger 
EAT volumes and higher risk of AF. Our results do not sug-
gest EAT as a mediating factor between thyroid function and 
AF. However, the occurrence of AF may be influenced by 
potential synergistic effects between thyroid hormones and 
EAT. Future research is warranted to replicate our results and 
provide further insight into the relationship between thyroid 
function and AF.
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Supplementary materials
Table S1 Association of Z-scores of TSH or FT4 with waist circumferencea
Variable Model 1, odds ratio (95% CI) Model 2, odds ratio (95% CI)
TSH 1.17 (1.06, 1.28) 1.13 (1.02, 1.25)
FT4 0.82 (0.73, 0.92) 0.84 (0.74, 0.94)
Notes: Model 1 = age, sex, cohort, alcohol, smoking, and time between laboratory measurement and scan; Model 2 = Model 1 + total cholesterol, HDL cholesterol, serum 
lipid-lowering medication, systolic blood pressure, diastolic blood pressure, blood pressure-lowering medication, prevalent diabetes, prevalent CHD. aWC was stratified 
according to sex-specific clinical cutoffs. For women, small WC was defined as ≤88 cm, while large WC was defined as >88 cm. For men, small WC was defined as ≤102 cm, 
while large WC was defined as >102 cm.
Abbreviations: CHD, coronary heart disease; FT4, free thyroxine; HDL, high-density lipoprotein; TSH, thyroid-stimulating hormone; WC, waist circumference.
Table S2 Proportions of the effect of Z-scores of FT4 on AF due to mediation and/or interaction with EAT, using all confounders of 
M → Y relation separately
Excess risk 95% CI Proportion attributable, %
Small WC
CDE 0.076 (−0.154, 0.305) 84.3
INTref −0.001 (−0.061, 0.024) −1.2
INTmed 0.004 (−0.011, 0.014) 4.0
PIE 0.012 (−0.014, 0.031) 12.9
Total 0.090 (−0.140, 0.306) 100
Large WC
CDE 0.394 (−0.043, 0.675) 77.6
INTref 0.080 (−0.149, 0.282) 15.6
INTmed 0.013 (−0.038, 0.045) 2.5
PIE 0.022 (−0.019, 0.046) 4.3
Total 0.508 (0.063, 0.765) 100
Notes: WC was stratified according to sex-specific clinical cutoffs. For women, small WC was defined as ≤88 cm, while large WC was defined as >88 cm. For men, small 
WC was defined as ≤102 cm, while large WC was defined as >102 cm. M →Y refer to mediatior → outcome.
Abbreviations: AF, atrial fibrillation; CDE, controlled direct effect; EAT, epicardial fat tissue; FT4, free thyroxine; INTmed, mediated interaction; INTref, reference interaction; 
PIE, pure indirect effect; WC, waist circumference.
Figure S1 Directed acyclic graph for the association of free thyroxine (FT4) with epicardial adipose tissue (EAT)  corresponds to Table 2, Model 1.
Notes: A=FT4, M=EAT, C=Age, sex, cohort, smoking, alcohol, and time between measurements. L=Waist circumference (WC), Effect modification of FT4 by WC 
(interaction FT4WC P<0.05) on M, not included in the primary model.
L C
MA
Figure S2 Directed acyclic graph for the association of FT4 with atrial fibrillation (AF)  corresponds to Table 3, model 1.
Notes: A=FT4, Y=AF, C=age, sex, cohort, smoking, alcohol, and time between measurements, (large) waist circumference (WC). Effect modification of FT4 by WC 
(interaction FT4WC P<0.05) on Y.
A Y
C
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
5.
5.
11
8.
63
 o
n 
19
-J
un
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Epidemiology 2018:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Clinical Epidemiology
Publish your work in this journal
Submit your manuscript here: https://www.dovepress.com/clinical-epidemiology-journal
Clinical Epidemiology is an international, peer-reviewed, open access, 
online journal focusing on disease and drug epidemiology, identifica-
tion of risk factors and screening procedures to develop optimal pre-
ventative initiatives and programs. Specific topics include: diagnosis, 
prognosis, treatment, screening, prevention, risk factor modification, 
systematic reviews, risk and safety of medical interventions, epidemiol-
ogy and biostatistical methods, and evaluation of guidelines, translational 
medicine, health policies and economic evaluations. The manuscript 
management system is completely online and includes a very quick 
and fair peer-review system, which is all easy to use.
Dovepress
234
Bos et al
Figure S3 Directed acyclic graph for the association of EAT with AF  corresponds to Table 3, model 2.
Notes: M=EAT, Y=AF, C=1 refers to the set of confounders in model 1 of table 3. 2 refers to model 2. Age, sex, cohort, smoking, alcohol, FT4, thyroid-stimulating 
hormone, and time between measurements. 2. Total cholesterol, high-density lipoprotein (HDL) cholesterol, lipid-lowering medication, diastolic blood pressure, systolic 
blood pressure, blood pressure-lowering medication, prevalent coronary heart disease (CHD), and prevalent diabetes. L=WC (omitted in this model due to colinearity with 
M). No interactions observed.
Abbreviations: AF, atrial fibrillation; EAT, epicardial adipose tissu; WC, waist circumference.
M
C
Y
L
Figure S4 Final Directed acyclic graph,, stratified by waist circumference dichotomized according to sex-specific clinical cutoffs.
Notes: A=FT4, M=EAT, Y=AF, C1=age, sex, cohort, smoking, alcohol, and time between measurements, C2=age, sex, cohort, smoking, alcohol, predicted values using the 
following variables: total cholesterol, HDL cholesterol, lipid-lowering medication, diastolic blood pressure, systolic blood pressure, blood pressure-lowering medication, 
prevalent CHD, and prevalent diabetes (sensitivity analysis with original covariates), C3=age, sex, cohort, smoking, and alcohol.
Abbreviations: AF, atrial fibrillation; CHD, coronary heart disease; EAT, epicardial fat tissue; FT4, free thyroxine.
A M Y
C1 C2
C3
Building final DAG for mediation analysis
Conditions: 
1. The effect the exposure A has on the outcome Y is unconfounded conditional on C 
2. The effect the mediator M has on the outcome Y is unconfounded conditional on (CA)
3. The effect the exposure A has on the mediator M is unconfounded conditional on C 
4. None of the mediator-outcome confounders are themselves affected by the exposure.
•	 Condition 4 is violated due to the relationship of A with several individual variables C; however, A is not associ-
ated with the composite of these variables (predicted value of variables ii on M).
•	 Due to interaction of FT4 with WC, all analyses are stratified by large and small WC (sex-specific clinical cutoffs).
Figure S5 Building Final DAG.
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